Lipid-lowering drugs and inflammatory bowel disease’s risk: a drug-target Mendelian randomization study

被引：0
作者：
Jiaxi Zhao
Rong Chen
Mengqi Luo
Hongping Gong
Kaixin Li
Qian Zhao
机构：
[1] Sichuan University,General Practice Ward/International Medical Center Ward General Practice Medical Center, West China Hospital
[2] Sun Yat-Sen University,Department of Rehabilitation Medicine, The First Affiliated Hospital
[3] Sichuan University,Department of Gastroenterology and Hepatology, West China Hospital
[4] Huadong Hospital,Department of Nephrology
来源：
Diabetology & Metabolic Syndrome | / 16卷
关键词：
Inflammatory bowel disease; Lipid- lowering drug; Mendelian randomization; Crohn’s disease; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
What is already known? IBD were associated with lipid-lowering drugs in previous studies, but the causal relationship is unknown. There were two studies exploring the relationship, but the results were inconsistant.
引用
收藏
相关论文
共 130 条
[1]  
Zhang YZ(2014)Inflammatory bowel disease: pathogenesis World J Gastroenterol 20 91-9
[2]  
Li YY(2019)Inflammatory bowel disease presentation and diagnosis Surg Clin North Am 99 1051-1062
[3]  
Flynn S(2016)Inflammatory bowel disease Nature 540 S97-2778
[4]  
Eisenstein S(2017)Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Lancet 390 2769-1587
[5]  
Hodson R(2021)The burden of inflammatory bowel disease in Europe in 2020 J Crohns Colitis 15 1573-309
[6]  
Ng SC(2022)Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells Int Immunopharmacol 107 108698-1249
[7]  
Shi HY(2021)Treatments of inflammatory bowel disease toward personalized medicine Arch Pharm Res 44 293-621
[8]  
Hamidi N(2022)Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease J Am Geriatr Soc 71 1243-24
[9]  
Zhao M(2023)Update lipidology : evidence-based treatment of dyslipidemia Inn Med 64 611-82
[10]  
Gönczi L(1966)Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal Drug Saf 14 11-14
12345678910